118 related articles for article (PubMed ID: 21296067)
1. Down-regulation of ICBP90 contributes to doxorubicin resistance.
Wang J; Song Y; Xu S; Zhang Q; Li Y; Tang D; Jin S
Eur J Pharmacol; 2011 Apr; 656(1-3):33-8. PubMed ID: 21296067
[TBL] [Abstract][Full Text] [Related]
2. The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation.
Quan ZW; Yang Y; Li JY; Gong W; Qin YY; Li SG
Biomed Pharmacother; 2010 Sep; 64(7):451-7. PubMed ID: 20359855
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of nuclear protein ICBP90 by p53/p21Cip1/WAF1-dependent DNA-damage checkpoint signals contributes to cell cycle arrest at G1/S transition.
Arima Y; Hirota T; Bronner C; Mousli M; Fujiwara T; Niwa S; Ishikawa H; Saya H
Genes Cells; 2004 Feb; 9(2):131-42. PubMed ID: 15009091
[TBL] [Abstract][Full Text] [Related]
4. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
[TBL] [Abstract][Full Text] [Related]
5. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylation of ICBP90 by protein kinase A enhances topoisomerase IIalpha expression.
Trotzier MA; Bronner C; Bathami K; Mathieu E; Abbady AQ; Jeanblanc M; Muller CD; Rochette-Egly C; Mousli M
Biochem Biophys Res Commun; 2004 Jun; 319(2):590-5. PubMed ID: 15178447
[TBL] [Abstract][Full Text] [Related]
7. ICBP90, a novel human CCAAT binding protein, involved in the regulation of topoisomerase IIalpha expression.
Hopfner R; Mousli M; Jeltsch JM; Voulgaris A; Lutz Y; Marin C; Bellocq JP; Oudet P; Bronner C
Cancer Res; 2000 Jan; 60(1):121-8. PubMed ID: 10646863
[TBL] [Abstract][Full Text] [Related]
8. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
9. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
10. Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226.
Wang H; Jiang Zg; Wong YW; Dalton WS; Futscher BW; Chan VT
Biochem Biophys Res Commun; 1997 Aug; 237(2):217-24. PubMed ID: 9268689
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of topoisomerase IIalpha in CEM cells selected for merbarone resistance is associated with reduced expression of Sp3.
Mo YY; Wang Q; Beck WT
Cancer Res; 1997 Nov; 57(22):5004-8. PubMed ID: 9371492
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism research in somatostatin reverting the chemosensitivity of GBC-SD cell line].
Qin YY; Li JY; Li SG; Yue JN; Quan ZW
Zhonghua Wai Ke Za Zhi; 2008 Mar; 46(5):381-3. PubMed ID: 18785538
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of human topoisomerase IIalpha correlates with altered expression of transcriptional regulators NF-YA and Sp1.
Allen KA; Williams AO; Isaacs RJ; Stowell KM
Anticancer Drugs; 2004 Apr; 15(4):357-62. PubMed ID: 15057140
[TBL] [Abstract][Full Text] [Related]
14. Human multiple myeloma cells are sensitized to topoisomerase II inhibitors by CRM1 inhibition.
Turner JG; Marchion DC; Dawson JL; Emmons MF; Hazlehurst LA; Washausen P; Sullivan DM
Cancer Res; 2009 Sep; 69(17):6899-905. PubMed ID: 19690141
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of topoisomerase IIalpha expression in advanced gallbladder carcinoma: a potential chemotherapeutic target.
Washiro M; Ohtsuka M; Kimura F; Shimizu H; Yoshidome H; Sugimoto T; Seki N; Miyazaki M
J Cancer Res Clin Oncol; 2008 Jul; 134(7):793-801. PubMed ID: 18204862
[TBL] [Abstract][Full Text] [Related]
16. Genomic structure and chromosomal mapping of the gene coding for ICBP90, a protein involved in the regulation of the topoisomerase IIalpha gene expression.
Hopfner R; Mousli M; Garnier JM; Redon R; du Manoir S; Chatton B; Ghyselinck N; Oudet P; Bronner C
Gene; 2001 Mar; 266(1-2):15-23. PubMed ID: 11290415
[TBL] [Abstract][Full Text] [Related]
17. TCR pathway involves ICBP90 gene down-regulation via E2F binding sites.
Abbady AQ; Bronner C; Bathami K; Muller CD; Jeanblanc M; Mathieu E; Klein JP; Candolfi E; Mousli M
Biochem Pharmacol; 2005 Aug; 70(4):570-9. PubMed ID: 15964557
[TBL] [Abstract][Full Text] [Related]
18. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
19. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
20. Reduced activity of topoisomerase II in an Adriamycin-resistant human stomach-adenocarcinoma cell line.
Son YS; Suh JM; Ahn SH; Kim JC; Yi JY; Hur KC; Hong WS; Muller MT; Chung IK
Cancer Chemother Pharmacol; 1998; 41(5):353-60. PubMed ID: 9523730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
